glp 1 agonist dpp 4 inhibitor Inhibition of DPP-4. Food consumption boosts the release of GLP-1 and It's the first in a
Description
Findings are not yet published but available from the US FDA including placebo-corrected and dose-dependent declines in bone mineral density of 0.9%1.2% at total hip, 0.3%0.7% at lumbar spine, and 0.1% at femoral neck with the use of canagliflozin
2019;139:e56-528
GLP-1 RAs are currently being investigated for various new areas, such as cardiovascular diseases, non-alcoholic steatohepatitis (NASH), Alzheimers disease, and chronic kidney disease
Its generally safe for diabetics but its side effects and variable effectiveness in non-diabetics mean proceed with caution
